Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jan 1;97(1):73–80. doi: 10.1172/JCI118409

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

E Masson 1, M V Relling 1, T W Synold 1, Q Liu 1, J D Schuetz 1, J T Sandlund 1, C H Pui 1, W E Evans 1
PMCID: PMC507064  PMID: 8550853

Abstract

Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL) and is commonly given in high doses. However, the rationale for high-dose MTX (HDMTX) has been challenged recently. To determine whether higher MTX polyglutamate (MTXPG) concentrations in ALL blasts translate into greater antileukemic effects, 150 children with newly diagnosed ALL were randomized to initial treatment with either HDMTX (1,000 mg/m2 intravenously over 24 h) or lower-dose MTX (30 mg/m2 by mouth every 6 h x 6). ALL blasts accumulated higher concentrations of MTXPG and long-chain MTXPG (MTXPGLC) after HDMTX (P < 0.00001). Of 101 patients evaluable for peripheral blast cytoreduction, MTXPG concentrations were higher in patients whose blast count decreased within 24 h (P = 0.005) and in those who had no detectable circulating blasts within 4 days (P = 0.004). The extent of inhibition of de novo purine synthesis in ALL blasts was significantly related to the blast concentration of MTXPGLC (IC95% = 483 pmol/10(9) blasts). The percentage of patients with 44-h MTXPGLC exceeding the IC95% was greater after HDMTX (81%) than LDMTX (46%, P < 0.0001). These data indicate that higher blast concentrations of MTXPG are associated with greater antileukemic effects, establishing a strong rationale for HD-MTX in the treatment of childhood ALL.

Full Text

The Full Text of this article is available as a PDF (198.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra C. J., Drake J. C., Jolivet J., Chabner B. A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881–4885. doi: 10.1073/pnas.82.15.4881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balinska M., Nimec Z., Galivan J. Characteristics of methotrexate polyglutamate formation in cultured hepatic cells. Arch Biochem Biophys. 1982 Jul;216(2):466–476. doi: 10.1016/0003-9861(82)90235-1. [DOI] [PubMed] [Google Scholar]
  3. Barredo J. C., Synold T. W., Laver J., Relling M. V., Pui C. H., Priest D. G., Evans W. E. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood. 1994 Jul 15;84(2):564–569. [PubMed] [Google Scholar]
  4. Bertino J. R. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol. 1993 Jan;11(1):5–14. doi: 10.1200/JCO.1993.11.1.5. [DOI] [PubMed] [Google Scholar]
  5. Bökkerink J. P., Bakker M. A., Hulscher T. W., De Abreu R. A., Schretlen E. D. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol. 1988 Jun 15;37(12):2321–2327. doi: 10.1016/0006-2952(88)90358-9. [DOI] [PubMed] [Google Scholar]
  6. Chabner B. A., Allegra C. J., Curt G. A., Clendeninn N. J., Baram J., Koizumi S., Drake J. C., Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep;76(3):907–912. doi: 10.1172/JCI112088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chessells J. M., Bailey C., Richards S. M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet. 1995 Jan 21;345(8943):143–148. doi: 10.1016/s0140-6736(95)90164-7. [DOI] [PubMed] [Google Scholar]
  8. Evans W. E., Crom W. R., Abromowitch M., Dodge R., Look A. T., Bowman W. P., George S. L., Pui C. H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986 Feb 20;314(8):471–477. doi: 10.1056/NEJM198602203140803. [DOI] [PubMed] [Google Scholar]
  9. Fabre I., Fabre G., Goldman I. D. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res. 1984 Aug;44(8):3190–3195. [PubMed] [Google Scholar]
  10. Gajjar A., Ribeiro R., Hancock M. L., Rivera G. K., Mahmoud H., Sandlund J. T., Crist W. M., Pui C. H. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995 Aug 15;86(4):1292–1295. [PubMed] [Google Scholar]
  11. Goldman I. D. Effects of methotrexate on cellular metabolism: some critical elements in the drug-cell interaction. Cancer Treat Rep. 1977 Jul;61(4):549–558. [PubMed] [Google Scholar]
  12. Goldman I. D. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci. 1971 Nov 30;186:400–422. doi: 10.1111/j.1749-6632.1971.tb46996.x. [DOI] [PubMed] [Google Scholar]
  13. Gurney J. G., Severson R. K., Davis S., Robison L. L. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995 Apr 15;75(8):2186–2195. doi: 10.1002/1097-0142(19950415)75:8<2186::aid-cncr2820750825>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  14. Göker E., Lin J. T., Trippett T., Elisseyeff Y., Tong W. P., Niedzwiecki D., Tan C., Steinherz P., Schweitzer B. I., Bertino J. R. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia. 1993 Jul;7(7):1000–1004. [PubMed] [Google Scholar]
  15. Henderson G. B., Suresh M. R., Vitols K. S., Huennekens F. M. Transport of folate compounds in L1210 cells: kinetic evidence that folate influx proceeds via the high-affinity transport system for 5-methyltetrahydrofolate and methotrexate. Cancer Res. 1986 Apr;46(4 Pt 1):1639–1643. [PubMed] [Google Scholar]
  16. Kamen B. A., Weitman S. D. High-dose methotrexate: is it warranted? Pediatr Hematol Oncol. 1994 Mar-Apr;11(2):135–137. doi: 10.3109/08880019409141647. [DOI] [PubMed] [Google Scholar]
  17. Kamen B. A., Winick N. J. High dose methotrexate therapy: insecure rationale? Biochem Pharmacol. 1988 Jul 15;37(14):2713–2715. doi: 10.1016/0006-2952(88)90032-9. [DOI] [PubMed] [Google Scholar]
  18. Kamen B. A., Winick N. Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol. 1986;122:339–346. doi: 10.1016/0076-6879(86)22191-6. [DOI] [PubMed] [Google Scholar]
  19. Look A. T., Melvin S. L., Williams D. L., Brodeur G. M., Dahl G. V., Kalwinsky D. K., Murphy S. B., Mauer A. M. Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood. 1982 Oct;60(4):959–967. [PubMed] [Google Scholar]
  20. Masera G., Jankovic M., Zurlo M. G., Locasciulli A., Rossi M. R., Uderzo C., Recchia M. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr. 1982 Jan;100(1):152–155. doi: 10.1016/s0022-3476(82)80259-x. [DOI] [PubMed] [Google Scholar]
  21. Matherly L. H., Barlowe C. K., Phillips V. M., Goldman I. D. The effects on 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis of the selectivity of leucovorin rescue. J Biol Chem. 1987 Jan 15;262(2):710–717. [PubMed] [Google Scholar]
  22. Miller D. R., Coccia P. F., Bleyer W. A., Lukens J. N., Siegel S. E., Sather H. N., Hammond G. D. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989 Dec;7(12):1807–1815. doi: 10.1200/JCO.1989.7.12.1807. [DOI] [PubMed] [Google Scholar]
  23. Miller R. W., Young J. L., Jr, Novakovic B. Childhood cancer. Cancer. 1995 Jan 1;75(1 Suppl):395–405. doi: 10.1002/1097-0142(19950101)75:1+<395::aid-cncr2820751321>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  24. Niemeyer C. M., Gelber R. D., Tarbell N. J., Donnelly M., Clavell L. A., Blattner S. R., Donahue K., Cohen H. J., Sallan S. E. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991 Nov 15;78(10):2514–2519. [PubMed] [Google Scholar]
  25. Patte C., Kalifa C., Flamant F., Hartmann O., Brugières L., Valteau-Couanet D., Bayle C., Caillaud J. M., Lemerle J. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20(2):105–113. doi: 10.1002/mpo.2950200204. [DOI] [PubMed] [Google Scholar]
  26. Patte C., Philip T., Rodary C., Zucker J. M., Behrendt H., Gentet J. C., Lamagnère J. P., Otten J., Dufillot D., Pein F. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991 Jan;9(1):123–132. doi: 10.1200/JCO.1991.9.1.123. [DOI] [PubMed] [Google Scholar]
  27. Pui C. H. Childhood leukemias. N Engl J Med. 1995 Jun 15;332(24):1618–1630. doi: 10.1056/NEJM199506153322407. [DOI] [PubMed] [Google Scholar]
  28. Pui C. H., Crist W. M. Biology and treatment of acute lymphoblastic leukemia. J Pediatr. 1994 Apr;124(4):491–503. doi: 10.1016/s0022-3476(05)83125-7. [DOI] [PubMed] [Google Scholar]
  29. Pui C. H., Crist W. M., Look A. T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 1990 Oct 15;76(8):1449–1463. [PubMed] [Google Scholar]
  30. Pui C. H., Simone J. V., Hancock M. L., Evans W. E., Williams D. L., Bowman W. P., Dahl G. V., Dodge R. K., Ochs J., Abromowitch M. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. Leukemia. 1992 Feb;6(2):150–157. [PubMed] [Google Scholar]
  31. Rautonen J., Hovi L., Siimes M. A. Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood. 1988 Apr;71(4):989–991. [PubMed] [Google Scholar]
  32. Reiter A., Schrappe M., Ludwig W. D., Hiddemann W., Sauter S., Henze G., Zimmermann M., Lampert F., Havers W., Niethammer D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994 Nov 1;84(9):3122–3133. [PubMed] [Google Scholar]
  33. Riehm H., Feickert H. J., Schrappe M., Henze G., Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus. 1987;30:139–146. doi: 10.1007/978-3-642-71213-5_21. [DOI] [PubMed] [Google Scholar]
  34. Schorin M. A., Blattner S., Gelber R. D., Tarbell N. J., Donnelly M., Dalton V., Cohen H. J., Sallan S. E. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr;12(4):740–747. doi: 10.1200/JCO.1994.12.4.740. [DOI] [PubMed] [Google Scholar]
  35. Synold T. W., Relling M. V., Boyett J. M., Rivera G. K., Sandlund J. T., Mahmoud H., Crist W. M., Pui C. H., Evans W. E. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994 Nov;94(5):1996–2001. doi: 10.1172/JCI117552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Teresi M. E., Crom W. R., Choi K. E., Mirro J., Evans W. E. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987 May;110(5):788–792. doi: 10.1016/s0022-3476(87)80025-2. [DOI] [PubMed] [Google Scholar]
  37. Trump D. L., Egorin M. J., Forrest A., Willson J. K., Remick S., Tutsch K. D. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 1991 Nov;9(11):2027–2035. doi: 10.1200/JCO.1991.9.11.2027. [DOI] [PubMed] [Google Scholar]
  38. Whitehead V. M., Rosenblatt D. S., Vuchich M. J., Shuster J. J., Witte A., Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood. 1990 Jul 1;76(1):44–49. [PubMed] [Google Scholar]
  39. Whitehead V. M., Vuchich M. J., Lauer S. J., Mahoney D., Carroll A. J., Shuster J. J., Esseltine D. W., Payment C., Look A. T., Akabutu J. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1992 Sep 1;80(5):1316–1323. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES